Anavex Life Sciences Regains Compliance with Nasdaq Periodic Filing Requirement

Anavex Life Sciences has filed its delayed 2026 quarterly reports, removing a Nasdaq listing compliance risk and keeping AVXL on the Global Select Market.

Rhea-AI Summary

Anavex Life Sciences (AVXL) has regained compliance with Nasdaq's periodic filing requirement, ensuring continued listing of its common stock.

The company received confirmation from Nasdaq that it now complies with Listing Rule 5250(c)(1), which requires timely filing of all periodic reports with the SEC. Anavex filed its outstanding Form 10-Qs for the second and third fiscal quarters of 2026 on August 28, 2026. With these submissions, the company is in compliance with all Nasdaq listing standards and its shares will continue to trade on the Nasdaq Global Select Market under the ticker AVXL.

Positive

• Nasdaq compliance restored after filing outstanding Q2 and Q3 2026 Form 10-Qs on August 28, 2026
• Continued Nasdaq Global Select Market listing for AVXL common stock with all listing standards met

Negative

• Previous delay in SEC filings highlighted by the need to file outstanding Form 10-Qs for two 2026 quarters

Argus Sep 3 session 2 alerts

-1.38% close to close 0.9x rel. volume Open Argus

Details

News Market Reaction – AVXL

-7.3% Trough Tracked

$292.00M Mkt Cap at Peak Alert

On Sep 3, the first trading day after this news, AVXL closed 1.38% below the previous close. Argus tracked a trough of -7.3% from its starting point during tracking. Our momentum scanner recorded 2 alerts in the available session data.

Data tracked by StockTitan Argus for the Sep 3 session.

Key Figures

Nasdaq listing rule: Rule 5250(c)(1) Outstanding filings: Q2 and Q3 fiscal 2026 Form 10-Q filings Filing date: August 28, 2026 +1 more

Nasdaq listing rule

Rule 5250(c)(1)

Periodic SEC filing requirement

Outstanding filings

Q2 and Q3 fiscal 2026 Form 10-Q filings

Filed with the SEC on August 28, 2026

Filing date

August 28, 2026

Date the outstanding Form 10-Q filings were submitted

Core indications

Three

Indications referenced in the announcement headline

Historical Context

5 past events · Latest: Aug 25

5 events

1. Aug 25

   Q3 earnings report

   24h Move

   +14.5%

   Q3 results included $7.8 million net income and a clinical program update

2. Aug 17

   Stockholder letter

   24h Move

   -0.3%

   Stockholder letter sought support for six director nominees

3. Aug 11

   Proxy materials

   24h Move

   +3.5%

   Definitive proxy materials disclosed Nasdaq delinquency and meeting details

4. Aug 03

   Board refresh plans

   24h Move

   +7.3%

   Company announced board refresh plans to oversee clinical progress

5. Jul 30

   Q2 earnings report

   24h Move

   +8.4%

   Preliminary loss narrowed and a Nasdaq compliance plan was submitted

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

nasdaq listing rule 5250(c)(1), form 10-q, cns

3 terms

nasdaq listing rule 5250(c)(1) regulatory

"regained compliance with Nasdaq Listing Rule 5250(c)(1)"

Nasdaq Listing Rule 5250(c)(1) requires companies listed on the Nasdaq stock exchange to promptly notify the exchange if their stock price falls below a certain minimum level, known as the "initial listing standards." This rule helps ensure that investors are aware of significant declines in a company's stock value, which could signal financial trouble or increased risk. Essentially, it helps maintain transparency and protect investors by keeping them informed about important changes in a company's stock performance.

form 10-q regulatory

"filed its outstanding Form 10-Q filings for the second and third fiscal quarters"

A Form 10-Q is a detailed report that publicly traded companies are required to file with regulators three times a year, providing an update on their financial health and business activities. It is important for investors because it offers timely insights into a company's performance, helping them make informed decisions about buying or selling stocks. Think of it as a regular check-up report that shows how well a company is doing.

cns medical

"treatments for central nervous system (“CNS”) diseases"

CNS stands for the central nervous system, the brain and spinal cord that control thought, movement and bodily functions. For investors, CNS-focused products and research matter because therapies aimed at this “delicate wiring” are scientifically challenging, often carry higher development and regulatory risk, and can take longer to prove safe and effective — but successful treatments also tend to command large markets and premium pricing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Anavex Life Sciences is Pleased to Regain Full Compliance with Nasdaq, Continues to Execute on Clinical Development Strategy and Advance all Three Core Indications Forward

NEW YORK, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for central nervous system (“CNS”) diseases with high unmet medical needs, today announced that it has received confirmation from The Nasdaq Stock Market LLC (“Nasdaq”) that the Company has regained compliance with Nasdaq Listing Rule 5250(c)(1), which requires Nasdaq-listed companies to file all required periodic filings with the Securities and Exchange Commission (“SEC”).

On August 28, 2026, the Company filed its outstanding Form 10-Q filings for the second and third fiscal quarters of 2026 with the SEC. The Company is now in compliance with all Nasdaq listing standards, and its common stock will continue to trade on the Nasdaq Global Select Market under the ticker "AVXL."

About Anavex Life Sciences Corp.

Anavex Life Sciences Corp. (Nasdaq: AVXL) is a publicly traded clinical stage biopharmaceutical company engaged in the development of novel therapeutics for the treatment of central nervous system (“CNS”) diseases with high unmet medical need. Further information is available at www.anavex.com.

Forward-Looking Statements

Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements include, but are not limited to, statements relating to the Company’s ability to continue trading on the Nasdaq Global Select Market. These statements are based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such forward-looking statements due to various factors, including, but not limited to, risks related to the Company’s ability to maintain compliance with the Nasdaq Listing Rules; and other risks and uncertainties set forth in the Company’s Annual Report on Form 10-K for the fiscal year ended September 30, 2025, filed with the Securities and Exchange Commission (“SEC”) on November 25, 2025, the Company’s Quarterly Report on Form 10-Q for the quarterly period ended December 31, 2025, filed with the SEC on February 9, 2026, the Company’s Form 10-K/A for the fiscal year ended September 30, 2025, filed with the SEC on August 28, 2026, the Company’s Form 10-Q/A for the quarterly period ended December 31, 2025, filed with the SEC on August 28, 2026, the Company’s Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2026, filed with the SEC on August 28, 2026, the Company’s Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2026, filed with the SEC on August 28, 2026, and subsequent filings and furnishings with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and Anavex Life Sciences Corp. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof except as required by law.

Investor Relations & Media Contact:

SCR Partners, LLC
Alex Arzeno
Tel: 203-550-3972
Email: alex@scr-ir.com 

Tripp Sullivan
Tel: 615-942-7077
Email: tsullivan@scr-ir.com 

Company Contact:

Sandra Boenisch
Principal Financial Officer
Anavex Life Sciences Corp.
Tel: 1-844-689-3939
Email: ir@anavexcorp.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Anavex Life Sciences (AVXL) announce regarding Nasdaq compliance?

Anavex Life Sciences announced that Nasdaq confirmed the company has regained compliance with Nasdaq Listing Rule 5250(c)(1), which requires all periodic SEC filings to be current, so its common stock will continue trading on the Nasdaq Global Select Market under the ticker AVXL.

Why is Nasdaq Listing Rule 5250(c)(1) important for Anavex Life Sciences AVXL shareholders?

Nasdaq Listing Rule 5250(c)(1) requires listed companies to file all required periodic reports with the SEC. By regaining compliance, Anavex removes a listing risk and confirms that AVXL shares will continue to trade on the Nasdaq Global Select Market under existing terms.

When did Anavex Life Sciences file its outstanding Form 10-Q reports?

Anavex Life Sciences filed its outstanding Form 10-Q reports for the second and third fiscal quarters of 2026 with the SEC on August 28, 2026, bringing its periodic filings current and allowing it to regain Nasdaq compliance.

Does Anavex Life Sciences AVXL remain listed on the Nasdaq Global Select Market?

Yes. After filing its outstanding 2026 quarterly Form 10-Qs and regaining compliance with Nasdaq Listing Rule 5250(c)(1), Anavex Life Sciences states that its common stock will continue to trade on the Nasdaq Global Select Market under the ticker AVXL.

What type of company is Anavex Life Sciences (AVXL)?

Anavex Life Sciences (AVXL) is described as a publicly traded, clinical-stage biopharmaceutical company developing novel therapeutics for central nervous system (CNS) diseases with high unmet medical need, and its common stock trades on the Nasdaq Global Select Market.